Ross Moat

CIK: 0001857177

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)22 (24.2%)

Position reduction

Option Exercises (M)39 (42.9%)

Derivative conversions

Awards (A)19 (20.9%)

Compensation grants

Other (G, F, J, C, D, …)11 (12.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KNSA

Kiniksa Pharmaceuticals International, plc

Discretionary Trading P&L

Holdings

Transaction History (91 total)

KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
9.4K shares at avg. $18.06$170K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
722 shares at avg. $94.05$68K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
6.3K shares at avg. $22.89$143K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
8.9K shares at avg. $92.05$822K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
6.7K shares at avg. $91.23$610K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
11.6K shares at avg. $93.15$1.1M
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
12.3K shares at avg. $21.77$268K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
1.7K shares at avg. $12.97$22K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
16.1K shares at avg. $17.76$286K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
8.4K shares at avg. $93.97$792K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
10.9K shares at avg. $18.06$197K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
3.7K shares at avg. $96.03$353K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
37.8K shares at avg. $92.00$3.5M
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
15.1K shares at avg. $92.81$1.4M
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
1.8K shares at avg. $97.10$171K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
3.8K shares at avg. $11.97$45K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
2.6K shares at avg. $97.76$252K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
6.3K shares at avg. $94.92$596K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
21.1K shares at avg. $11.10$234K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
16.1K shares at avg. $10.76$173K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.5K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Tax Payment(F)
Direct
4K shares at avg. $79.28$318K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.5K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
1.7K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
1.6K shares-

		Type	Shares	Price		Ownership
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	9,412	$18.06	$169,981	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	722	$94.05	$67,904	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	6,263	$22.89	$143,360	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	8,932	$92.05	$822,191	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	6,681	$91.23	$609,508	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	11,642	$93.15	$1,084,452	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	12,302	$21.77	$267,815	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,658	$12.97	$21,504	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	16,112	$17.76	$286,149	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	8,430	$93.97	$792,167	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	10,895	$18.06	$196,764	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	3,672	$96.03	$352,622	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	37,775	$92.00	$3,475,300	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	15,114	$92.81	$1,402,730	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	1,760	$97.10	$170,896	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	3,760	$11.97	$45,007	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	2,575	$97.76	$251,732	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	6,282	$94.92	$596,287	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	21,059	$11.10	$233,755	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	16,111	$10.76	$173,354	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,477	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	4,007	$79.28	$317,675	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,457	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,740	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,611	-	$0	Direct

1-25 of 91 transactions

About Moat Ross

Moat Ross (SEC CIK 0001857177) files insider reports with the SEC as CHIEF OPERATING OFFICER of Kiniksa Pharmaceuticals International, plc (KNSA).

Signal8 holds 15 ownership filings by Moat Ross, all Form 4s, filed between Sep 4, 2024 and Nov 3, 2026. Those filings report 91 transactions, from Jul 15, 2024 to Nov 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Moat Ross's filings is in LONDON.

Recent filings by Moat Ross

Nov 2, 2026: Option exercise of KNSA shares (Form 4, code M).
Nov 2, 2026: Open-market sale of KNSA shares (Form 4, code S).
Nov 2, 2026: Option exercise of KNSA shares (Form 4, code M).
Nov 2, 2026: Open-market sales of KNSA shares (3 lines, Form 4, code S).
Nov 2, 2026: Option exercise of KNSA shares (Form 4, code M).

Other insiders filing for Kiniksa Pharmaceuticals International, plc (KNSA)

Patel Sanj K, CHAIRMAN & CEO
Ragosa Mark, CHIEF FINANCIAL OFFICER
Paolini John F., CHIEF MEDICAL OFFICER
Megna Michael R, CHIEF ACCOUNTING OFFICER
Quart Barry D, Director
Levy Richard S, Director

How to read Form 4 transaction codes